



## CME Session 8

Thyroid + Dosimetry Committee

**Monday, September 11, 16:45-18:15**

### Session Title

**Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumours**

### Chairpersons

**Valentina Ambrosini** (Bologna, Italy)

**Rudolf Werner** (Würzburg, Germany)

### Programme

16:45 - 17:05 **Irene J. Virgolini** (Innsbruck, Austria): PRRT Combinations in On-Going Trials

17:05 - 17:25 **Lilja B. Solnes** (Baltimore, U.S.): RECIST and Beyond: How Can Radiological Assessment Be Improved?

17:25 - 17:50 **Valentina Ambrosini** (Bologna, Italy): Functional Nuclear Medicine Parameters (Predictive and/or Prognostic)

17:50 - 18:15 **Jonathan Strosberg** (Tampa, U.S.): How to Structure Pts' Follow-Up After PRRT: Guidelines and Beyond

### Educational Objectives

1. To gain knowledge on current on-going clinical trials of combination therapies with PRRT and to understand the underlying potential synergistic therapeutic effects
2. To describe the varying radiological response parameters for patients scheduled for PRRT (including RECIST and beyond)
3. To describe the varying functional nuclear medicine predictive and prognostic response parameters for patients scheduled for PRRT
4. To describe how to structure patient's follow-up after PRRT (including between-cycle, intermediate and long-term follow-up)

### Summary

This CME session is dedicated to response assessment of patients afflicted with neuroendocrine tumours (NET) scheduled for peptide receptor radionuclide therapy (PRRT). First, an overview of on-going clinical trials focusing on combination therapies with PRRT will be presented and the underlying potential synergistic therapeutic effects will be highlighted. Second, varying radiological response parameters for patients scheduled for PRRT will be explained, including RECIST and beyond. This will then be followed by the predictive and prognostic roles of functional nuclear medicine parameters. Last, a structured overview on how to plan patient's follow-up after PRRT will be provided (including between-cycle, intermediate and long-term follow-up).



**Key Words**

PRRT, peptide receptor radionuclide therapy, neuroendocrine tumor, neuroendocrine neoplasm, NET, DOTATATE, DOTATOC, DOTANOC, biomarker, response, liquid biopsy